Depressive symptoms and plasma monoamine levels as predictors of resoinse to clozapine treatment in adolescents with schizophrenia;Depressive symptome und biogene amine als pradiktoren der therapieresponse bei schizophrenen erkrankungen im kindesund jugendalter

Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie

Volumn 26, Issue 4, 1998, Pages 235-243

  Fleischhaker, Ch ^a   Schulz, E ^a   Remschmidt, H ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Adolescents; Biogenic amines; Clozapine; Schizophrenia

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; BIOGENIC AMINE; CLOZAPINE; NEUROLEPTIC AGENT; NORADRENALIN;

ADOLESCENT; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; DEPRESSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; HUMAN; MALE; NORADRENALIN BLOOD LEVEL; PREDICTION; RATING SCALE; SCHIZOPHRENIA;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; CLOZAPINE; DEPRESSION; FEMALE; HUMANS; MALE; NEUROTRANSMITTER AGENTS; PROGNOSIS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0031774666     PISSN: 03016811     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Ackenheil, M.: Pharmacokinetic investigations and biochemical effects in man. Psychopharmacology 99, 32-37, 1989.
2. American Psychiatric Association: Diagnostic and statistical manual of mental disorders (3rd ed. rev.). Washington, DC 1987.
3. Andreasen, N. C.: Negative symptoms in schizophrenia: Definition and reliability. Archives of General Psychiatry 39, 784-788, 1982.
4. Andreasen, N. C.: The Scale for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa 1984a.
5. Andreasen, N. C.: The Scale for the Assessment of Positive Symptoms (SAPS). Iowa City: University of Iowa 1984b.
6. Andreasen, N. C.; Flaum, M.; Arndt, S.; Alliger, R.; Swayze, V. W.: Positive and negative symptoms: Assessment and validity. In: Marneros, A.; Andreasen, N. C.; Tsuang, M. T. (Eds.). Negative versus positive schizophrenia, 28-51. Springer, Berlin, Heidelberg 1991.
7. Banki, C. M.: Alterations of cerebrospinal fluid 5-hydroxyindoleacetic acid and total blood serotonin content during clozapine treatment. Psychopharmacology 56, 195-198, 1978.
8. Birmaher, B.; Baker, R.; Kapur, S.; Quintana, H.; Ganguli, R.: Clozapine for the treatment of adolescents with schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry 31, 160-164, 1992.
9. Blanz, B.; Schmidt, M. H.: Clozapine for schizophrenia (letter). Journal of the American Academy of Child and Adolescent Psychiatry 32, 223-224, 1993.
10. Breier, A.; Buchanan, R. W.; Waltrip, R. W.; Listwak, S.; Holmes, G.; Goldstein, D. S.: The effect of clozapine on plasma norepinephrine: Relationship to clinical efficacy. Neuropsychopharmacology 10, 1-7, 1994.
11. Elliger, T.; Englert, E.; Freisleder, F. J.; Friedrich, M.; Gierow, B.; Holstein, K.; Linder, M.; Remschmidt, H.; Resch, F.; Schmidt, M. H.; Schulz, E.; Trott, G. E.; Warnke, A.: Zur Behandlung schizophrener Psychosen des Kindes- und Jugendalters mit Clozapin (Leponex). Konsensuskonferenz vom 4. März 1994. Kinder- und Jugendpsychiatrie. Zeitschrift für Kinder. Jugendpsychiatrie 22, 325-327, 1994.
12. Frazier, J. A.; Gordon, C. T.; McKenna, K.; Lenane, M. C.; Jih, D.; Rapoport, J. L.: An open trial of clozapine in 11 adolescents with childhood-onset schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry 33, 658-663, 1994.
13. Gordon, C. T.; Frazier, J. A.; McKenna, K.; Giedd, J.; Zametkin, A.; Zahn, T.; Hommer, D.; Hong, W.; Kaysen, D.; Albus, K. E.; Rapoport, J. L.: Childhood-onset schizophrenia: An NIMH study in progress. Schizophrenia Bulletin 20, 697-712, 1994.
14. Green, A. I.; Alam, M. Y.; Sobieraj, J. T.; Pappalardo, K. M.; Waternaux, C.; Salzman, C.; Schatzberg, A. F.; Schildkraut, J. J.: Clozapine response and plasma catecholamines and their metabolites. Psychiatry Research 46, 139-149, 1993.
15. Kahn, R. S.; Davidson, M.: On the value of measuring dopamine, norepinephrine and their metabolites in schizophrenia. Neuropsychopharmacology 8, 93-95, 1993.
16. Kronig, M. H.; Munne, R. A.; Szymanski, S.; Safferman, A. Z.; Pollack, S.; Cooper, T.; Kane, J. M.; Lieberman, J. A.: Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. American Journal of Psychiatry 152, 179-182, 1995.
17. Lieberman, J.; John, C.; Pollack, S.; Masier, S.; Bookstein, P.; Cooper, T.; Iadorola, M.; Kane, J.: Biochemical effects of clozapine in cerebrosinal fluid of patients with schizophrenia. In: Tamminga, C. A.; Schulz, S. (Eds.). Schizophrenia Research, Vol. 1, 341-349. Raven Press, New York 1991.
18. Meltzer, H. Y.: Predictors of response to clozapine. Psychiatric Annals 26, 385-389, 1996.
19. Miller, D. D.; Fleming, F.; Holman, T.; Perry, P. J.: Plasma clozapine concentrations as a predictor of clinical response: A follow-up study. Journal of Clinical Psychiatry 55, 117-121, 1994.
20. Moscarelli, M.; Maffei, C.; Cesana, B. M.; Boato, B.: An international perspective on assessment of negative and positive symptoms in schizophrenia. American Journal of Psychiatry 144, 1595-1598, 1987.
21. Mozes, T.; Toren, P.; Chernauzan, N.; Mester, R.; Yoranhegesh, R.; Blumensohn, R.; Weizman, A.: Clozapine treatment in very early onset schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry 33, 65-70, 1994.
22. Overall, J. E.; Gorham, D. R.: The Brief Psychiatric Rating Scale. Psychological Reports 10, 799-812, 1962.
23. Pickar, D.; Owen, R. R.; Litman, R. E.; Konicki, P. E.; Gutierrez, R.; Rapaport, M. H.: Clinical and biologic response to clozapine in patients with schizophrenia: Crossover comparison with fluphenazine. Archives of General Psychiatry 49, 345-353, 1992.
24. Piscitelli, S. C.; Frazier, J. A.; McKenna, K.; Albus, K. E.; Grothe, D. R.; Gordon, C. T.; Rapoport, J. L.: Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia - Association with response. Journal of Clinical Psychiatry 55, 94-97, 1994.
25. Potkin, S. G.; Bera, R.; Gulasekaram, B.; Cota, J.; Hayes, S.; Jin, Y.; Richmond, G.; Carreon, D.; Sitanggan, K.; Gerber, B.: Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. Journal of Clinical Psychiatry 55, 133-136, 1994.
26. Remschmidt, H.; Martin, M.; Schulz, E.; Gutenbrunner, C.; Fleischhaker, C.: The concept of positive and negative schizophrenia in child and adolescent psychiatry. In: Marneros, A.; Andreasen, N. C.; Tsuang, M. T. (Eds.). Negative versus positive schizophrenia, 219-242. Springer, Berlin, Heidelberg 1991.
27. Remschmidt, H.; Schulz, E.; Martin, M.: Die Behandlung schizophrener Psychosen in der Adoleszenz mit Clozapine (Leponex). In: Naber, D.; Müller-Spahn, F. (Hrsg.). Clozapine. Pharmakologie und Klinik eines atypischen Neuroleptikums, 99-119. Schattauer, New York 1992.
28. Remschmidt, H.; Schulz, E.; Martin, M.: An open trial of clozapine in thirty-six adolescents with schizophrenia. Journal of Child and Adolescent Psychopharmacology 4, 31-41, 1994.
29. Remschmidt, H.; Schulz, E.; Martin, M.; Warnke, A.; Trott, G.-E.: Childhood-onset schizophrenia: History of the concept and recent studies. Schizophrenia Bulletin 20, 727-745, 1994.
30. Remschmidt, H.; Schulz, E.; Hepertz-Dahlmann, B.: Schizophrenic psychoses with manifestation in childhood and adolescence: A guide to diagnosis and drug choice. CNS Drugs 6, 100-112, 1996.
31. Riederer, P.; Laux, G.: Therapeutic drug monitoring of psychotropics: Report of a consensus conference. Pharmacopsychiatry 25, 271-272, 1992.
32. Siefen, G.; Remschmidt, H.: Behandlungsergebnisse mit Clozapin bei schizophrenen Jugendlichen. Zeitschrift für Kinder- und Jugendpsychiatrie 14, 245-257, 1986.
33. Schulz, E.; Fleischhaker, C.; Remschmidt, H.: Determination of clozapine and its major metabolites in serum samples of adolescent schizophrenic patients by high performance liquid chromatography. Data from a prospective clinical trial. Pharmacopsychiatry 28, 20-25, 1995.
34. Schulz, E.; Fleischhaker, C.; Remschmidt, H.: Correlated changes in symptoms and neurotransmitter indices during maintenance treatment with clozapine or conventional neuroleptics in adolescents and young adults with schizophrenia. Journal of Child and Adolescent Psychopharmacology 6, 119-131, 1996.
35. Schulz, E.; Fleischhaker, C.; Remschmidt, H.: Clozapine metabolism in early-onset schizophrenia. Abstracts of the Xth Congress of the European College of Neuropsychopharmacology. European Neuropsychopharmacology 7, Supplement 2, 132, 1997.
36. Schulz, E.; Fleischhaker, C.; Clement, H. C.; Remschmidt, H.: Blood biogenic amines during clozapine treatment of early-onset schizophrenia. Journal of Neural Transmission 104, 1077-1089, 1997.
37. Schulz, E.: Verlaufsprädiktoren schizophrener Psychosen in der Adoleszenz. Entwicklungspsychopathologische, neurochemische und psychopharmakologische Befunde. Hogrefe, Göttingen, Bern, Toronto, Seattle 1998.
38. Towbin, K. E.; Dykens, E. M.; Pugliese, R. G.: Clozapine for early developmental delays with childhood-onset schizophenia - Protocol and 15-month outcome. Journal of the American Academy of Child and Adolescent Psychiatry 33, 651-657, 1994.